BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.
Authors: Zahida Qamri, Anju Preet, Mohd W. Nasser, Caroline E. Bass, Gustavo Leone, et al
Molecular Cancer Therapeutics, November 2009
—
Cannabinoids have been reported to possess antitumorogenic activity. Not much is known, however, about the effects and mechanism of action of synthetic nonpsychotic cannabinoids on breast cancer growth and metastasis. We have shown that the cannabinoid receptors CB1 and CB2 ar…
Cannabinoids for Tourette’s Syndrome.
Authors: Adrienne Curtis, Carl E Clarke, Hugh E Rickards
Cochrane Database of Systematic Reviews, 7 October 2009
—
BACKGROUND: Gilles de la Tourette Syndrome (GTS) is a developmental neuropsychiatric disorder characterised by the presence of chronic motor and phonic tics. Drugs currently used in the treatment of GTS either lack efficacy or are associated with intolerable side effects. Ther…
Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.
Authors: N. Olea-Herrero, D. Vara, S. Malagarie-Cazenave, I. Díaz-Laviada
British Journal of Cancer, 15 September 2009
—
BACKGROUND: We have previously shown that cannabinoids induce growth inhibition and apoptosis in prostate cancer PC-3 cells, which express high levels of cannabinoid receptor types 1 and 2 (CB(1) and CB(2)). In this study, we investigated the role of CB(2) receptor in the anti…
Assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005.
Authors: Martin Frisher, Ilana Crome, Orsolina Martino, Peter Croft
Schizophrenia Research, September 2009
—
A recent systematic review concluded that cannabis use increases risk of psychotic outcomes independently of confounding and transient intoxication effects. Furthermore, a model of the association between cannabis use and schizophrenia indicated that the incidence and prevalen…
The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities.
Authors: Tamás Bíró, Balázs I. Tóth, György Haskó, Ralf Paus, Pál Pacher
Trends in Pharmacological Sciences, August 2009
—
The newly discovered endocannabinoid system (ECS; comprising the endogenous lipid mediators endocannabinoids present in virtually all tissues, their G-protein-coupled cannabinoid receptors, biosynthetic pathways and metabolizing enzymes) has been implicated in multiple regulat…
Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia.
Authors: Glenn Schwarcz, Basawaraj Karajgi, Richard McCarthy
Journal of Clinical Psychopharmacology, June 2009
—
We are reporting improvement of symptoms of schizophrenia in a small group of patients who received the cannabinoid agonist dronabinol (synthetic Delta-9-tetrahydrocannabinol). Before this report, cannabinoids had usually been associated with worsening of psychotic symptoms. I…
The emerging role of the endocannabinoid system in cardiovascular disease.
Authors: Pál Pacher, Sabine Steffens
Seminars in Immunopathology, June 2009
—
Endocannabinoids are endogenous bioactive lipid mediators present both in the brain and various peripheral tissues, which exert their biological effects via interaction with specific G-protein-coupled cannabinoid receptors, the CB(1) and CB(2). Pathological overactivation of t…
Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium.
Authors: Vikas Tyagi, Brian J. Philips, Ruthie Su, Marc C. Smaldone, Vickie L. Erickson, et al
The Journal of Urology, April 2009
—
PURPOSE: Although cannabinoid receptor expression has been demonstrated in human brain and other peripheral neuronal tissues, definitive expression of these receptors in the human bladder has not been reported. Consequently we investigated the expression of functional cannabin…
Cannabinoid hyperemesis syndrome: clinical diagnosis of an underrecognised manifestation of chronic cannabis abuse.
Authors: Siva P. Sontineni, Sanjay Chaudhary, Vijaya Sontineni, Stephen J. Lanspa
World Journal of Gastroenterology, 14 March 2009
—
Cannabis is a common drug of abuse that is associated with various long-term and short-term adverse effects. The nature of its association with vomiting after chronic abuse is obscure and is underrecognised by clinicians. In some patients this vomiting can take on a pattern si…
The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD).
Authors: George A. Fraser
CNS Neuroscience & Therapeutics, Winter 2009
—
This is the report of an open label clinical trial to evaluate the effects of nabilone, an endocannabinoid receptor agonist, on treatment-resistant nightmares in patients diagnosed with posttraumatic stress disorder (PTSD). METHODS: Charts of 47 patients diagnosed with PTSD an…
Cannabis and breastfeeding.
Authors: Aurélia Garry, Virginie Rigourd, Ammar Amirouche, Valérie Fauroux, Sylvie Aubry, Raphaël Serreau
Journal of Toxicology, 2009
—
Cannabis is a drug derived from hemp plant, Cannabis sativa, used both as a recreational drug or as medicine. It is a widespread illegal substance, generally smoked for its hallucinogenic properties. Little is known about the adverse effects of postnatal cannabis exposure thro…
Neuroanatomic comparison of bipolar adolescents with and without cannabis use disorders.
Authors: Kelly Jarvis, Melissa P. DelBello, Neil Mills, Igor Elman, Stephen M. Strakowski, Caleb M. Adler
Journal of Child and Adolescent Psychopharmacology, December 2008
—
OBJECTIVE: Co-occurrence of substance use and bipolar disorders is both common and associated with poor treatment response and greater functional impairment than either disorder alone. The neurophysiological correlates of this co-morbidity however, remain unclear. In this pilo…